Heart showdown: which diabetes drug wins?

NCT ID NCT07203677

Completed Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at two diabetes drugs, tirzepatide and sitagliptin, to see which one better prevents heart attacks, strokes, or death in people with type 2 diabetes and heart disease. Researchers analyzed data from over 49,000 patients. The goal was to learn how well real-world data can mimic clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide and sitagliptin
What this could lead to: If tirzepatide proves better, it could become a preferred option for managing diabetes and reducing heart risks.
What could go wrong: This is an observational study using existing data, not a controlled trial, so results may be less reliable. It also cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TYPE2 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.